Gilles Berger is a Principal Investigator and Assistant Professor at the University of Brussels (Université Libre de Bruxelles). He is a chemist and pharmacist with broad interest in organic and theoretical chemistry, drug discovery, biomedical sciences and oncology. He has conducted research in Brussels, Paris, Montreal and Boston, where he has gathered hands-on experience at the interface of drug design, nanotechnologies, biology and human disease. In recent years, he has developed as a translational scientist, allowing the use of his complementary multi-disciplinary skills toward the advancement of various projects, such as drug discovery and cancer therapy, organocatalysis, theoretical chemistry and halogen bonding. At the Wyss, he is advancing intracranial immunotherapies for brain cancers, combining the use of innovative biodegradable brain implants with activators of innate immunity and checkpoint inhibitors, with the goal to modulate the cold and immunosuppressive tumor micro-environment that is unfortunately found in the very aggressive primary brain tumor, glioblastoma.
Dr. Berger has received numerous awards and fellowships, such as Fulbright, BAEF, the UCB’s Young Investigator Award and worked as a Fellow of the Belgian Science foundation (FNRS). His work has been published in top journals, including numerous covers. Besides his appointments in Brussels and at the Wyss, he is a Research Associate at MIT. He received his Pharm.D. (magna cum laude) and Ph.D. from the University of Brussels, then worked as a postdoc with Stephen Hanessian (University of Montréal), Stephen Lippard (MIT) and Sean Lawler (Harvard Medical School).